文献速递心力衰竭与心肌病

抑制纤连蛋白聚合减轻小鼠心衰模型心肌纤维化并改善心功能

Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure.
PubMed 文献 · Circulation · 2018-01-01

该研究在小鼠及人类心脏成纤维细胞中评估纤连蛋白聚合抑制剂pUR4的作用,并在缺血再灌注(I/R)小鼠模型中每日腹腔注射pUR4或对照肽7天。结果显示pUR4减少活化成纤维细胞的纤连蛋白和胶原沉积、抑制增殖与迁移,在体内减少肌成纤维细胞标志物和中性粒细胞浸润,并持续4周改善心功能、减轻不良重构和纤维化;成纤维细胞特异性敲除纤连蛋白基因同样产生保护作用,且加用pUR4无额外获益。

要点

  • pUR4抑制纤连蛋白聚合可减少活化成纤维细胞的胶原沉积、增殖和迁移。
  • I/R后每日pUR4治疗7天减少肌成纤维细胞标志物和中性粒细胞浸润。
  • pUR4治疗持续4周改善心功能、减轻不良重构和纤维化,成纤维细胞Fn敲除同样保护。

核心结论

  • 抑制纤连蛋白聚合或心脏成纤维细胞纤连蛋白基因表达可减轻肌成纤维细胞病理特征,并改善体内心衰模型的 adverse 重构和纤维化。
  • 干扰纤连蛋白聚合可能成为治疗心脏纤维化和心力衰竭的新策略。

研究设计与样本

  • 体外使用小鼠和人类心脏肌成纤维细胞评估pUR4对增殖、迁移、细胞外基质沉积及相关机制的影响。
  • 体内野生型小鼠在心脏手术后立即每日腹腔注射pUR4或对照肽III-11C,连续7天,于I/R后7天或4周分析。
  • 使用可诱导的成纤维细胞限制性纤连蛋白基因敲除小鼠(Tcf21MerCreMer; Fnflox)评估纤连蛋白表达的细胞特异性。

主要发现

  • pUR4处理活化的肌成纤维细胞减少纤连蛋白和胶原沉积到细胞外基质,并减弱细胞增殖,可能通过降低c-myc信号介导。
  • pUR4改善成纤维细胞迁移,伴随β1整合素内化增加和磷酸化黏着斑激酶蛋白水平降低。
  • 体内每日pUR4治疗7天显著减少I/R后肌成纤维细胞标志物和中性粒细胞浸润。
  • 该治疗方案在I/R后长达4周显著减轻心肌功能障碍、病理性心脏重构和纤维化。
  • I/R后成纤维细胞中诱导性敲除纤连蛋白基因产生显著功能心脏保护,减少肥厚和纤维化;在纤连蛋白敲除小鼠中加用pUR4未提供进一步心脏保护。

临床怎么用

  • 在缺血再灌注相关心衰模型中,短期(7天)抑制纤连蛋白聚合可带来持续至4周的心脏功能和结构获益。
  • 纤连蛋白聚合抑制剂的作用可能主要针对心脏成纤维细胞谱系分泌的纤连蛋白。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fibronectin (FN) polymerization is necessary for collagen matrix deposition and is a key contributor to increased abundance of cardiac myofibroblasts (MFs) after cardiac injury. We hypothesized that interfering with FN polymerization or its genetic ablation in fibroblasts would attenuate MF and fibrosis and improve cardiac function after ischemia/reperfusion (I/R) injury. METHODS: Mouse and human MFs were used to assess the impact of the FN polymerization inhibitor (pUR4) in attenuating pathological cellular features such as proliferation, migration, extracellular matrix deposition, and associated mechanisms. To evaluate the therapeutic potential of inhibiting FN polymerization in vivo, wild-type mice received daily intraperitoneal injections of either pUR4 or control peptide (III-11C) immediately after cardiac surgery for 7 consecutive days. Mice were analyzed 7 days after I/R to assess MF markers and inflammatory cell infiltration or 4 weeks after I/R to evaluate long-term effects of FN inhibition on cardiac function and fibrosis. Furthermore, inducible, fibroblast-restricted, FN gene-ablated (Tcf21MerCreMer; Fnflox) mice were used to evaluate cell specificity of FN expression and polymerization in the heart. RESULTS: pUR4 administration on activated MFs reduced FN and collagen deposition into the extracellular matrix and attenuated cell proliferation, likely mediated through decreased c-myc signaling. pUR4 also ameliorated fibroblast migration accompanied by increased β1 integrin internalization and reduced levels of phosphorylated focal adhesion kinase protein. In vivo, daily administration of pUR4 for 7 days after I/R significantly reduced MF markers and neutrophil infiltration. This treatment regimen also significantly attenuated myocardial dysfunction, pathological cardiac remodeling, and fibrosis up to 4 weeks after I/R. Last, inducible ablation of FN in fibroblasts after I/R resulted in significant functional cardioprotection with reduced hypertrophy and fibrosis. The addition of pUR4 to the FN-ablated mice did not confer further cardioprotection, suggesting that the salutary effects of inhibiting FN polymerization may be mediated largely through effects on FN secreted from the cardiac fibroblast lineage. CONCLUSIONS: Inhibiting FN polymerization or cardiac fibroblast gene expression attenuates pathological properties of MFs in vitro and ameliorates adverse cardiac remodeling and fibrosis in an in vivo model of heart failure. Interfering with FN polymerization may be a new therapeutic strategy for treating cardiac fibrosis and heart failure.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Valiente-Alandi I, Potter SJ, Salvador AM, et al. Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure. Circulation. 2018. PMID: 29653926. doi:10.1161/CIRCULATIONAHA.118.034609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。